Pro Tip: Learn how to use HBI Alerts to follow your favorite topics

HBI Spotlight

 

Inflexion acquires German medtech Primed from Paragon Partners

European mid-market private equity firm Inflexion has bought Primed Group, a German manufacturer of medical consumables and sterilisation services, from DACH-focused private equity investor Paragon Partners. HBI understands the deal value is just under €300 million.
July 16, 2026

Bupa acquires Australia’s Partnered Health Group

British multinational health insurer Bupa is acquiring Australian integrated healthcare provider Partnered Health Group from private equity firm Quadrant Private Equity. Bupa’s acquisition of Partnered Health reflects a broader shift among health insurers towards vertical integration, as payors look to move beyond the traditional model of reimbursing medical costs and take a more active role in delivering care. 
June 25, 2026

GSK acquires Nuvalent for $10.6 billion

British drugmaker GSK has acquired Nuvalent, a Boston-based clinical-stage biopharmaceutical company focused on precisely targeted oncology therapies, for an equity value of $10.6 billion (~£8 billion).
June 17, 2026

Terveystalo buys Finnish ophthalmology provider Silmäasema

Terveystalo, Finland’s second-largest private hospital group, is buying Silmäasema, a Finnish eye-care and optical retail company, for ~€574 million (partial share-swap deal). The seller is private equity firm CapMan Growth. €275 million of this will be paid in cash, and the rest will be funded through 36.5 million new Terveystalo shares.
June 11, 2026

HBI webinar on Value Creation in Healthcare Organisations

HBI hosted a webinar this week on the topic of value creation in healthcare organisations. The discussion looked at how healthcare providers are using digital tools, operational improvements and AI to build more connected and scalable organisations. Missed the webinar? Watch the recoding here.
June 11, 2026

France’s obesity drug reimbursement plan could reshape insurers’ role in care

France will begin reimbursing anti-obesity medicines from mid-June 2026, becoming the first EU country to introduce public coverage for treatments including Wegovy and Mounjaro, produced by Danish pharma giant Novo Nordisk and American pharmaceutical company Eli Lilly respectively. The policy is intended to prioritise high-risk patients rather than general weight management. Access will be limited to patients with severe obesity, defined as a BMI of at least 40, or at least 35 where accompanied by conditions such as type 2 diabetes or cardiovascular disease.
June 4, 2026

Mehiläinen buys Aleris to create €3.7bn revenue mega group

Finland-based pan-European healthcare group Mehiläinen is buying pan-Nordic outpatient group Aleris from private equity firm Triton, marking Mehiläinen’s entry into Norway and Denmark. The combined group will have €3.7 billion revenue and be present in nine countries, making it Europe’s largest outpatient-focused healthcare group.
May 21, 2026

Ares invests in German intensive care provider Linimed

California-based private equity and credit firm Ares Management is joining as a new financing partner for Linimed Gruppe, Germany’s largest provider of out-of-hospital intensive care. It will invest alongside existing lenders global asset management firm                        BlackRock and Hamburg-based investment firm Berenberg, while London-based private equity firm GHO Capital remains the company’s majority shareholder.
May 14, 2026
Older posts

Our Services

Company

Resources

Log in
Register
Log in
Register

Our Services

Company

Resources

Find Us